Roche Awards QSA and UCL Grant for Treatment Analysis Innovation
QSA in partnership with UCL Queen Square Institute of Neurology (IoN), and the UCL Centre for Medical Image Computing, have been awarded a multi-year collaborative grant funding by Roche to develop advanced neuroimaging biomarkers and novel AI tools for predicting response to treatments in people with progressive multiple sclerosis.
“Primary progressive multiple sclerosis is an incurable condition with unknown cause. This project will pave the way to develop new imaging tools which will allow us to detect treatment response faster, and with a smaller number of participants, hence expediting drug development for patients with this devastating condition.” - Professor Frederik Barkhof, QSA Co-Founder and project lead at the Queen Square Institute of Neurology.
Other investigators in the project include Dr James Cole (UCL Department of Computer Science) who, with Dr Eshaghi, will lead AI subprojects, and Dr Ferran Prados (UCL Department of Medical Physics & Biomedical Engineering) who will lead on advanced neuroimaging analysis.
“This project is an example of expedited translation of world-leading research at the UCL Queen Square Institute of Neurology to clinical trials and delivering benefits to patients.” - Dr Arman Eshaghi, QSA Co-Founder and Senior Research Fellow at the Queen Square MS Centre
Other investigators in the project include Dr Declan Chard (UCL co-leader of the project), Dr James Cole (UCL Department of Computer Science) who, with Dr Eshaghi, will lead AI subprojects, and Dr Ferran Prados (UCL Department of Medical Physics & Biomedical Engineering) who will lead on advanced neuroimaging analysis.
130,000 people in the UK, and more than 2.8 million globally, have multiple sclerosis. It is incurable, but we now have many highly effective treatments that prevent relapses (episodes of symptoms). However, many people with multiple sclerosis eventually develop progressive symptoms, and we only have two treatments for this. This project will address important questions about the treatment of progressive multiple sclerosis.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights, help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.